Emerging oligonucleotide therapeutics for rare neuromuscular diseases
Research and drug development concerning rare diseases are at the cutting edge of scientific technology. To date, over 7,000 rare diseases have been identified. Despite their individual rarity, 1 in 10 individuals worldwide is affected by a rare condition. For the majority of these diseases, there i...
Hoofdauteurs: | Aoki, Y, Wood, MJA |
---|---|
Formaat: | Journal article |
Taal: | English |
Gepubliceerd in: |
IOS Press
2021
|
Gelijkaardige items
-
Oligonucleotide-based therapies for neuromuscular disease
door: Douglas, A, et al.
Gepubliceerd in: (2015) -
Peptide-conjugate antisense based splice-correction for Duchenne muscular dystrophy and other neuromuscular diseases
door: Tsoumpra, MK, et al.
Gepubliceerd in: (2019) -
Advances in oligonucleotide drug delivery
door: Roberts, TC, et al.
Gepubliceerd in: (2020) -
Recent advances in antisense oligonucleotide therapy in genetic neuromuscular diseases
door: Ashok Verma
Gepubliceerd in: (2018-01-01) -
Cell-penetrating peptide conjugates of steric blocking oligonucleotides as therapeutics for neuromuscular diseases from a historical perspective to current prospects of treatment
door: Gait, M, et al.
Gepubliceerd in: (2018)